Overview

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Status:
Completed
Trial end date:
2000-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bone marrow that has been treated to remove certain white blood cells may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy, and may reduce the chance of developing graft-versus-host disease following bone marrow transplantation. PURPOSE: Phase IV trial to study the incidence of graft-versus-host disease in patients who have hematologic cancer and who are undergoing bone marrow transplantation from a donor.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland
University of Maryland, Baltimore
Collaborator:
University of Maryland Greenebaum Cancer Center
Treatments:
Antilymphocyte Serum
Cyclophosphamide
Thiotepa